BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology. 2013;268:431-439. [PMID: 23616632 DOI: 10.1148/radiol.13121637] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Bonekamp D, Bonekamp S, Halappa VG, Geschwind JF, Eng J, Corona-Villalobos CP, Pawlik TM, Kamel IR. Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma. Eur J Radiol. 2014;83:487-496. [PMID: 24387824 DOI: 10.1016/j.ejrad.2013.11.016] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
2 Valero V 3rd, Amini N, Spolverato G, Weiss MJ, Hirose K, Dagher NN, Wolfgang CL, Cameron AA, Philosophe B, Kamel IR, Pawlik TM. Sarcopenia adversely impacts postoperative complications following resection or transplantation in patients with primary liver tumors. J Gastrointest Surg 2015;19:272-81. [PMID: 25389056 DOI: 10.1007/s11605-014-2680-4] [Cited by in Crossref: 119] [Cited by in F6Publishing: 106] [Article Influence: 14.9] [Reference Citation Analysis]
3 Corona-villalobos CP, Pawlik TM, Kamel IR. Imaging of the Patient with a Biliary Tract or Primary Liver Tumor. Surgical Oncology Clinics of North America 2014;23:189-206. [DOI: 10.1016/j.soc.2013.10.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chapiro J, Duran R, Lin M, Schernthaner RE, Wang Z, Gorodetski B, Geschwind JF. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers. Radiology 2015;275:438-47. [PMID: 25531387 DOI: 10.1148/radiol.14141180] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
5 King MJ, Tong A, Dane B, Huang C, Zhan C, Shanbhogue K. Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. European Journal of Radiology 2020;133:109351. [DOI: 10.1016/j.ejrad.2020.109351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Shaghaghi M, AliyariG Hasabeh M, Ameli S, Ghadimi M, Hazhirkarzar B, Rezvani Habibabadi R, Tang H, Khoshpouri P, Wu Q, Pandey A, Pandey P, Baghdadi A, Kamel IR. Role of tumor margin and ADC change in defining the need for additional treatments after the first TACE in patients with unresectable HCC. Eur J Radiol 2020;133:109389. [PMID: 33166831 DOI: 10.1016/j.ejrad.2020.109389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner R, Wang Z, Tacher V, Savic LJ, Kamel IR, Geschwind JF. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology 2014;273:746-58. [PMID: 25028783 DOI: 10.1148/radiol.14140033] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 8.5] [Reference Citation Analysis]
8 Adam SZ, Miller FH. Imaging of the Liver Following Interventional Therapy for Hepatic Neoplasms. Radiologic Clinics of North America 2015;53:1061-76. [DOI: 10.1016/j.rcl.2015.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Ludwig JM, Camacho JC, Kokabi N, Xing M, Kim HS. The Role of Diffusion-Weighted Imaging (DWI) in Locoregional Therapy Outcome Prediction and Response Assessment for Hepatocellular Carcinoma (HCC): The New Era of Functional Imaging Biomarkers. Diagnostics (Basel) 2015;5:546-63. [PMID: 26854170 DOI: 10.3390/diagnostics5040546] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
10 Bonekamp S, Bonekamp D, Geschwind JF, Corona-Villalobos CP, Reyes DK, Pawlik TM, Kamel IR. Response stratification and survival analysis of hepatocellular carcinoma patients treated with intra-arterial therapy using MR imaging-based arterial enhancement fraction. J Magn Reson Imaging 2014;40:1103-11. [PMID: 24214827 DOI: 10.1002/jmri.24465] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
11 Hoogenboom TC, Thursz M, Aboagye EO, Sharma R. Functional imaging of hepatocellular carcinoma. Hepat Oncol 2016;3:137-53. [PMID: 30191034 DOI: 10.2217/hep-2015-0005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Nörthen A, Asendorf T, Shin HO, Hinrichs JB, Werncke T, Vogel A, Kirstein MM, Wacker FK, Rodt T. Parametric response mapping cut-off values that predict survival of hepatocellular carcinoma patients after TACE. Abdom Radiol (NY) 2018;43:3288-300. [PMID: 29680967 DOI: 10.1007/s00261-018-1610-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
13 Pandey P, Lewis H, Pandey A, Schmidt C, Dillhoff M, Kamel IR, Pawlik TM. Updates in hepatic oncology imaging. Surgical Oncology 2017;26:195-206. [DOI: 10.1016/j.suronc.2017.03.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Reiner CS, Morsbach F, Sah BR, Puippe G, Schaefer N, Pfammatter T, Alkadhi H. Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion. J Vasc Interv Radiol. 2014;25:747-759. [PMID: 24630751 DOI: 10.1016/j.jvir.2014.01.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
15 Klompenhouwer EG, Dresen RC, Verslype C, Laenen A, Bonne L, Vandecaveye V, Maleux G. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival. Cardiovasc Intervent Radiol 2018;41:1716-26. [DOI: 10.1007/s00270-018-1991-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Van Beers BE, Daire JL, Garteiser P. New imaging techniques for liver diseases. J Hepatol. 2015;62:690-700. [PMID: 25457198 DOI: 10.1016/j.jhep.2014.10.014] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
17 Corona-Villalobos CP, Halappa VG, Geschwind JF, Bonekamp S, Reyes D, Cosgrove D, Pawlik TM, Kamel IR. Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. Eur Radiol. 2015;25:380-390. [PMID: 25226843 DOI: 10.1007/s00330-014-3412-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
18 Wang Z, Chen R, Duran R, Zhao Y, Yenokyan G, Chapiro J, Schernthaner R, Radaelli A, Lin M, Geschwind JF. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2015;38:1548-56. [PMID: 26001366 DOI: 10.1007/s00270-015-1129-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
19 Chen BB, Murakami T, Shih TT, Sakamoto M, Matsui O, Choi BI, Kim MJ, Lee JM, Yang RJ, Zeng MS, Chen RC, Liang JD. Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer 2015;4:215-27. [PMID: 26734577 DOI: 10.1159/000367742] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
20 Xu L, Wang S, Wang S, Wang Y, Li W, Lin G, Yuan Z. Baseline apparent diffusion coefficients: Validation study of new predictor of survival in patients with unresectable hepatocellular carcinoma following chemoembolization. J Xray Sci Technol 2021;29:507-16. [PMID: 33814481 DOI: 10.3233/XST-200827] [Reference Citation Analysis]
21 Choi MH, Park GE, Oh SN, Park MY, Rha SE, Lee YJ, Jung SE, Choi JI. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization. Acad Radiol 2018;25:1363-73. [PMID: 29555570 DOI: 10.1016/j.acra.2018.02.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
22 Luedemann WM, Geisel D, Gebauer B, Schnapauff D, Chapiro J, Wieners G, Steffen I, Kahn J. Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT? Eur Radiol 2020;30:1601-8. [PMID: 31811428 DOI: 10.1007/s00330-019-06430-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
23 Yuan Z, Li WT, Ye XD, Zhu HY, Peng WJ. Novel functional magnetic resonance imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. Clin Transl Oncol. 2014;16:599-605. [PMID: 24356932 DOI: 10.1007/s12094-013-1147-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
24 Kim BK, Kim KA, Kim M, Park JY, Kim DY, Ahn SH, Han K, Kim SU, Park M. Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. Digestive and Liver Disease 2015;47:682-8. [DOI: 10.1016/j.dld.2015.04.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
25 Raoul JL, Adhoute X, Gilabert M, Edeline J. How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma. World J Hepatol 2016; 8(35): 1541-1546 [PMID: 28050234 DOI: 10.4254/wjh.v8.i35.1541] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
26 Ye X, Li W, Yuan Z. Is Volumetric Functional MR Imaging Superior to Current Anatomic Imaging Response Criteria for Hepatocellular Carcinoma after Intraarterial Therapy? Radiology 2014;271:619-20. [DOI: 10.1148/radiol.14132533] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Tacher V, Lin M, Duran R, Yarmohammadi H, Lee H, Chapiro J, Chao M, Wang Z, Frangakis C, Sohn JH. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. Radiology. 2016;278:275-284. [PMID: 26131913 DOI: 10.1148/radiol.2015142951] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
28 Reiner CS, Gordic S, Puippe G, Morsbach F, Wurnig M, Schaefer N, Veit-Haibach P, Pfammatter T, Alkadhi H. Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment. Cardiovasc Intervent Radiol. 2016;39:400-408. [PMID: 26216725 DOI: 10.1007/s00270-015-1185-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
29 Corona-Villalobos CP, Zhang Y, Zhang WD, Kamel IR. Magnetic resonance imaging of the liver after loco-regional and systemic therapy. Magn Reson Imaging Clin N Am 2014;22:353-72. [PMID: 25086934 DOI: 10.1016/j.mric.2014.04.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
30 Lewis H, Ghasabeh M, Khoshpouri P, Kamel I, Pawlik T. Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies. Surgical Oncology 2017;26:411-22. [DOI: 10.1016/j.suronc.2017.08.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
31 Corona-villalobos CP, Kamel IR. Functional Volumetric MRI in Assessing Treatment Response to Intra-Arterial Therapy of Primary and Secondary Liver Tumors: . Journal of Computer Assisted Tomography 2014;38:513-7. [DOI: 10.1097/rct.0000000000000072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
32 Labeur TA, Runge JH, Klompenhouwer EG, Klümpen HJ, Takkenberg RB, van Delden OM. Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation. Abdom Radiol (NY) 2019;44:2740-50. [PMID: 31069479 DOI: 10.1007/s00261-019-02030-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
33 Chapiro J, Lin M, Duran R, Schernthaner RE, Geschwind JF. Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI. Expert Rev Anticancer Ther 2015;15:199-205. [PMID: 25371052 DOI: 10.1586/14737140.2015.978861] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
34 Ronot M, Clift AK, Vilgrain V, Frilling A. Functional imaging in liver tumours. J Hepatol 2016;65:1017-30. [PMID: 27395013 DOI: 10.1016/j.jhep.2016.06.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
35 Zhu X, Sobhani F, Xu C, Pan L, Ghasebeh MA, Kamel IR. Quantitative volumetric functional MR imaging: an imaging biomarker of early treatment response in hypo-vascular liver metastasis patients after yttrium-90 transarterial radioembolization. Abdom Radiol (NY) 2016;41:1495-504. [PMID: 26960726 DOI: 10.1007/s00261-016-0694-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
36 Wang Z, Chapiro J, Schernthaner R, Duran R, Chen R, Geschwind JF, Lin M. Multimodality 3D Tumor Segmentation in HCC Patients Treated with TACE. Acad Radiol 2015;22:840-5. [PMID: 25863795 DOI: 10.1016/j.acra.2015.03.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
37 Bouda D, Lagadec M, Alba CG, Barrau V, Dioguardi Burgio M, Moussa N, Vilgrain V, Ronot M. Imaging review of hepatocellular carcinoma after thermal ablation: The good, the bad, and the ugly: Imaging of HCC After Thermal Ablation. J Magn Reson Imaging 2016;44:1070-90. [DOI: 10.1002/jmri.25369] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
38 Bargellini I, Crocetti L, Turini FM, Lorenzoni G, Boni G, Traino AC, Caramella D, Cioni R. Response Assessment by Volumetric Iodine Uptake Measurement: Preliminary Experience in Patients with Intermediate-Advanced Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization. Cardiovasc Intervent Radiol 2018;41:1373-83. [PMID: 29654507 DOI: 10.1007/s00270-018-1962-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
39 Lall C, Bhargava P, Sandrasegaran K, Shanbhogue AK, Ramsinghani N, Koh YW, Choi JY, Choi JI. Three-dimensional conformal radiation therapy in the liver: MRI findings along a time continuum. J Comput Assist Tomogr 2015;39:356-64. [PMID: 25700224 DOI: 10.1097/RCT.0000000000000219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
40 Corona-Villalobos CP, Halappa VG, Bonekamp S, Eng J, Reyes D, Cosgrove D, Rastegar N, Pan L, Pawlik TM, Kamel IR. Functional magnetic resonance imaging response of targeted tumor burden and its impact on survival in patients with hepatocellular carcinoma. Invest Radiol. 2015;50:283-289. [PMID: 25396692 DOI: 10.1097/rli.0000000000000112] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Luo Y, Pandey A, Ghasabeh MA, Pandey P, Varzaneh FN, Zarghampour M, Khoshpouri P, Ameli S, Li Z, Hu D, Kamel IR. Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization. Eur Radiol 2019;29:5160-71. [DOI: 10.1007/s00330-019-06100-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]